Free tool
FAERS Monitor: Truqap
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218197 or its brand name (Truqap, Capivasertib). Reports on generic versions are filed under their own applications.
Reports
3,065
Serious
2,565
84% of reports
Hospitalization
888
Death reported
590
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death465
- diarrhoea455
- rash400
- hyperglycaemia356
- malignant neoplasm progression175
- nausea164
- vomiting132
- fatigue129
- blood glucose increased128
- disease progression118
- diabetic ketoacidosis93
- pyrexia93
- erythema multiforme82
- decreased appetite81
- product dose omission issue79
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 6 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 827 |
| 2025 | 1,229 |
| 2026 | 991 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,094 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperglycaemiaSignal | 356 | 67.7 | 61.4 | 23,139 |
| erythema multiformeSignal | 82 | 60.9 | 49.1 | 4,728 |
| diabetic ketoacidosisSignal | 93 | 26.7 | 21.8 | 2,266 |
| malignant neoplasm progressionSignal | 175 | 11.7 | 10.2 | 1,715 |
| disease progressionSignal | 118 | 6.8 | 5.7 | 586 |
| rashSignal | 400 | 6.3 | 5.8 | 1,815 |
| diarrhoeaSignal | 455 | 4.8 | 4.4 | 1,425 |
| blood glucose increasedSignal | 128 | 4.7 | 3.9 | 368 |
| deathSignal | 465 | 3.7 | 3.4 | 954 |
| decreased appetiteSignal | 81 | 2.4 | 1.9 | 65 |
| vomiting | 132 | 1.9 | 1.6 | 59 |
| pyrexia | 93 | 1.8 | 1.5 | 36 |
| product dose omission issue | 79 | 1.8 | 1.5 | 30 |
| nausea | 164 | 1.4 | 1.2 | 21 |
| fatigue | 129 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.